Top Stories
In the BRAVE-AA-PEDS study, 42.4% of patients achieved a Severity of Alopecia Tool (SALT) score ≤20 at week 36.
Juvmo (tavapadon) was supported by a trio of Phase III wins in the TEMPO programme.
The ALK2 inhibitor approval comes just weeks after US regulators greenlit Regeneron's Pasatru for fibrodysplasia ossificans progressiva.
City Therapeutics joined the IPO queue, just a few months after bagging close to $100 million in a series B.
The nod expands Gazyva beyond its established uses in blood cancers and follows its October approval for active lupus nephritis.
Conference News
Newswise — BOSTON, September 27, 2026 — Low-dose radiation therapy may do more than relieve pain from early knee osteoarthritis, with a long-term analysis suggesting it could also influence how the di...
Newswise — BOSTON, September 27, 2026 — A short course of ultra-low-dose radiation therapy relieved painful bone lesions from multiple myeloma for most patients in a multi-institutional phase 2 clinic...
Investigator-led SwissNET registry analysis showed longer real-world progression-free and overall survival for patients re-treated with 177Lu-edotreotide compared to those receiving non-radiopharmace...
Research validates MiraDx’s PROSTOX® test, highlighting value of predictive radiation toxicity testing in prostate and other cancersLOS ANGELES--(BUSINESS WIRE)-- MiraDx, a molecular diagnostics compa...
Upright. From Concept to Clinical RealityBOSTON, Sept. 27, 2026 /PRNewswire/ -- Leo Cancer Care is marking a defining moment for radiation oncology as upright radiotherapy moves from concept to clinic...
